CMO Supplier Audit

OTC Brand Owner Supplier GMP Audit Checklist for CMO/CDMO Facilities

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Providing CMO/CDMO auditing guidelines for OTC brands, detailing 21 CFR 211 compliance checks, batch release systems, and quality agreements.

Key answer

The OTC drug brand owner is the legal distributor in the FDA registry and retains ultimate responsibility for product safety. Owners cannot delegate quality oversight based on "CMO has been inspected by FDA." Owners must conduct routine site audits of CMOs, evaluating batch release paths, change control triggers, and negotiating a pharmaceutical Quality Agreement.

Defining Responsibilities in a Quality Agreement

A Quality Agreement is distinct from a purchase contract; its core task is mapping quality system tasks and approval rights between owner and manufacturer.

  • Master record approval: the owner’s QA must approve final production/packaging SOPs
  • OOS notification: the CMO must notify the owner within 24-48 hours of any OOS results to run co-investigations
  • Batch release: the CMO provides manufacturing reports, but the owner retains final commercial release authority

FAQ

How does a CMO Warning Letter affect the brand owner?+

Yes. If the CMO is placed on Import Alert or shut down by the FDA, all products manufactured at the site are barred from sale. The brand faces immediate supply chain disruption and potential legal liability.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.